<DOC>
	<DOCNO>NCT00701077</DOCNO>
	<brief_summary>The Brugada syndrome rare disease potentially lead severe arrhythmic event otherwise healthy subjects.In many patient Implantable cardiovertor defibrillator ( ICD ) implant prevent sudden cardiac death . ICD however associate potential complication available countries.Pharmacological blockade specific ion channel ( Ito ) represent promising therapeutic approach syndrome.The 3,4-diaminopyridine ( 3,4-DAP ) pharmacological Ito blocker use humans.The aim study evaluate effect 3,4-DAP ventricular arrhythmia inducibility Brugada patient require electrophysiological study arrhythmic risk stratification .</brief_summary>
	<brief_title>DAPERB 3,4-DiAminoPyridine Electrophysiological Response Brugada Syndrome</brief_title>
	<detailed_description>Background : The Brugada syndrome rare disease potentially lead severe arrhythmic event otherwise healthy subjects.In many patient Implantable cardiovertor defibrillator ( ICD ) implant prevent sudden cardiac death . ICD however associate potential complication available countries.Pharmacological blockade specific ion channel ( Ito ) represent promising therapeutic approach syndrome . Experimental data show increase Ito current may associate ECG feature arrhythmogenic substrate observe syndrome . Moreover , Ito blockade reverse ECG abnormality suppress arrhythmogenicity.The 3,4-diaminopyridine ( 3,4-DAP ) pharmacological Ito blocker already use human another indication . Main objective : The aim study evaluate effect 3,4-DAP ventricular arrhythmia inducibility Brugada patient require electrophysiological study arrhythmic risk stratification . First end point : Re-inducibility non re-inducibility sustain ventricular arrhythmia electrophysiological study treatment Tested hypothesis : The 3,4-DAP decrease proportion re-inducibility electrophysiological study re-inducibility rate 80 % placebo group 25 % 3,4-DAP group Secondary objective : - ass effect 3,4-DAP ST segment elevation Brugada patient - describe relationship 3,4-DAP plasma concentration measure 45 minute electrophysiological study result ST segment elevation Study design : 2 centre , randomise , double blind , parallel group , placebo controlledA single dose 20 mg 3,4-DAP Included patient number patient : Included patient diagnose Brugada type 1 ECG require electrophysiological study arrhythmic risk stratification purpose . Only inducible patient include study.Using classical approach , hypothesis would 80 % placebo patient would re-inducible 25 % drug patient would . To test hypothesis , 32 patient ( 16 group ) would necessary ( a=5 % , b=20 % ) .Provided essential binary response electrophysiological study choose sequential approach order get opportunity stop success futility inclusion end study . The maximum number include patient 42 ( 21 group ) . Protocol duration : Study duration 48 hour patient.The protocol duration plan 5 year . Per protocol procedure : - Electrophysiological study ventricular program stimulation perform twice - Continuous ECG recording- Blood sample 3,4-DAP plasma concentration measurement Potential implication : If study hypothesis confirm would justify design long term efficacy study Brugada patient implant ICD .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Brugada Syndrome</mesh_term>
	<mesh_term>3,4-diaminopyridine</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Man woman â‰¥ 18 year old Brugada syndrome diagnose type 1 ECG either spontaneous druginduced Electrophysiological study indicate arrhythmic risk stratification purpose Inducibility sustain ventricular tachycardia ( &gt; 30 second ) ventricular fibrillation require defibrillation Physical medical examination Signed write informed consent Personal familial history epilepsy Pregnancy Body weight &gt; 100 kg need &gt; 1 counter shock defibrillation Alcohol cocaine consumption protocol Class I ( exception local anaesthesia lidocaine ) , II , III IV antiarrhythmic drug , antidepressant drug , ATP dependent potassium channel activator , sultopride stop &gt; 7 halvelives No medical insurance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Brugada syndrome</keyword>
	<keyword>Electrophysiological study</keyword>
	<keyword>Ion channel blockade</keyword>
</DOC>